Hemanext Receives $2.9M NIH Grant to Study Hypoxically Stored RBCs in SCD

October 15, 2025

Hemanext, an AABB corporate partner, has been awarded a $2.9 million Small Business Innovation Research phase II grant from the National Institutes of Health (NIH) to study the use of hypoxic red blood cells processed with the Hemanext ONE System in patients with sickle cell disease (SCD).

The three-year, multi-center, randomized trial will enroll patients aged seven and older to evaluate HRBC’s impact on hemoglobin A levels, transfusion burden and a range of clinical and laboratory outcomes, including quality of life measures.